Core Insights - Novartis and JD Health announced a deepened collaboration to accelerate the accessibility of global innovative medical solutions for Chinese patients [1][3] - The partnership aims to enhance digital health service capabilities and provide superior health management experiences [1][4] Collaboration Details - The collaboration between Novartis and JD Health has been ongoing for several years, focusing on leveraging their respective strengths to improve online accessibility of key products [1][3] - The recent agreement includes a formal launch of cooperation in the field of Chronic Spontaneous Urticaria (CSU), which affects over 10 million patients in China, particularly young women aged 20-40 [4][6] Strategic Goals - Novartis aims to break geographical barriers in accessing innovative drugs and solutions, aligning with China's "Healthy China 2030" strategy [3][4] - JD Health emphasizes the importance of digitalization as a driving force for innovation in the pharmaceutical industry and aims to leverage its platform advantages to enhance healthcare service delivery [4][6] Patient Focus - The collaboration will address the diverse needs of CSU patients, who often experience additional autoimmune diseases and psychological issues such as anxiety and depression [4][6] - Both companies are committed to building a service ecosystem in the CSU field to improve the accessibility of innovative medications and enhance patient quality of life [4][6]